|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C12Q 1/68 | (2006.01) |
| G01N 33/574 | (2006.01) |
| (11) | Number of the document | 2121989 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08742061.8 |
| Date of filing the European patent application | 2008-03-11 | |
| (97) | Date of publication of the European application | 2009-11-25 |
| (45) | Date of publication and mention of the grant of the patent | 2014-01-22 |
| (46) | Date of publication of the claims translation | 2014-05-26 |
| (86) | Number | PCT/US2008/003312 |
| Date | 2008-03-11 |
| (87) | Number | WO 2008/112269 |
| Date | 2008-09-18 |
| (30) | Number | Date | Country code |
| 906943 P | 2007-03-13 | US |
| (72) |
FREEMAN, Daniel, US
JUAN, Todd, US
RADINSKY, Robert, US
|
| (73) |
Amgen Inc.,
One Amgen Center Drive, Thousand Oaks, CA 91320-1799,
US
|
| (74) |
Genė Ona SRUOGIENĖ,
UAB TARPINĖ, A.P.Kavoliuko g. 24-152, LT-04328 Vilnius,
LT
|
| (54) | K-ras mutacijos ir anti-EGFr antikūnų terapija |
| K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY THERAPY |
| Payment date | Validity (years) | Amount | |
| 2026-02-19 | 19 | 347.00 EUR |
| 2027-03-11 |